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Abstract
Background: In the present study, we evaluated relationships between serum biomarkers and clinical/magnetic
resonance imaging (MRI) findings in golimumab-treated patients with ankylosing spondylitis.
Methods: In the GO-RAISE study, 356 patients with ankylosing spondylitis randomly received either placebo (n = 78)
or golimumab 50 mg or 100 mg (n = 278) injections every 4 weeks through week 24 (placebo-controlled); patients
continuing GO-RAISE received golimumab through week 252. Up to 139/125 patients had sera collected for
biomarkers/serial spine MRI scans (sagittal plane, 1.5-T scanner). Two blinded readers employed modified ankylosing
spondylitis spine magnetic resonance imaging score for activity (ASspiMRI-a) and ankylosing spondylitis spine
magnetic resonance imaging score for chronicity. Spearman correlations (rs) were assessed between serum
biomarkers (n = 73) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C-reactive-protein (CRP)-based
Ankylosing Spondylitis Disease Activity Score (ASDAS), modified Stokes Ankylosing Spondylitis Spine Score (mSASSS),
and ASspiMRI scores. Serum biomarkers predicting postbaseline spinal fatty lesion development and inflammation
were analyzed by logistic regression.
Results: Significant, moderately strong correlations were observed between baseline inflammatory markers interleukin
(IL)-6, intracellular adhesion molecule-1, complement component 3 (C3), CRP, haptoglobin, and serum amyloid-P and
baseline ASDAS (rs = 0.39–0.66, p≤ 0.01). Only baseline leptin significantly correlated with ASDAS improvement at week
104 (rs = 0.55, p = 0.040), and only baseline IL-6 significantly predicted mSASSS week 104 change (β = 0.236, SE = 0.073,
p = 0.002, model R2 = 0.093). By logistic regression, baseline leptin, C3, and tissue inhibitor of metalloproteinase (TIMP)-1
correlated with new fatty lesions per spinal MRI at week 14 and week 104 (both p < 0.01). Changes in serum C3 levels
at week 4 (rs = 0.55, p = 0.001) and week 14 (rs = 0.49, p = 0.040) significantly correlated with BASDAI improvement at
week 14. Baseline IL-6 and TIMP-1 (rs = −0.63, −0.67; p < 0.05) and reductions at week 4 in IL-6 (rs = 0.61, p < 0.05) and
C3 (rs = 0.72; p < 0.05) significantly correlated with week 14 ASspiMRI-a improvement.
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Conclusions: Extensive serum biomarker multiparametric analyses in golimumab-treated patients with ankylosing
spondylitis demonstrated few correlations with disease activity or MRI changes; IL-6 weakly correlated with
radiographic progression.
Trial registration: ClinicalTrials.gov identifier: NCT00265083. Registered on 12 December 2005.
Keywords: ASDAS, Biologic, Monoclonal antibody, MRI, TNF inhibitor
Background
Magnetic resonance imaging (MRI) is now an estab-
lished outcome instrument in the assessment of treat-
ment for ankylosing spondylitis (AS), based on results of
randomized, placebo-controlled studies. Such studies
have shown that MRI can provide an objective assess-
ment of response to tumor necrosis factor (TNF) inhib-
ition in patients with AS [1, 2].
In the GO-RAISE trial of golimumab in AS
(ClinicalTrials.gov identifier: NCT00265083), patients
with active AS showed significant improvement in
signs and symptoms after treatment with golimumab
[3] that were maintained through 2 years [4]. In the
MRI substudy of GO-RAISE, golimumab significantly
reduced MRI-detected spinal inflammation, and these ob-
served improvements correlated with improvement in
signs and symptoms of disease [5]. Data from observa-
tional studies suggest that long-term treatment with TNF
antagonists, especially if started early, may inhibit radio-
graphic progression [6]. In another study, a clear causal
relationship between the level of inflammation as assessed
by the Ankylosing Spondylitis Disease Activity Score
(ASDAS) and radiographic progression has been estab-
lished [7]. Moreover, a moderate relationship between
spinal inflammation detected by MRI and syndesmophyte
formation has been proven [8–11]. Therefore, we con-
ducted additional analyses of data from the GO-RAISE
trial to further assess potential relationships between
serum biomarkers of inflammation and clinical measures
of disease activity, as well as with spinal inflammation and
fatty lesions detected by MRI.
Methods
Patients and study design
The details of the GO-RAISE study have been described
previously [3, 4]. The protocol was reviewed and ap-
proved by the institutional review board or independent
ethics committee at each site of this multicenter trial.
(See Acknowledgements section below for further de-
tails.) All patients provided written informed consent.
The study was conducted at 57 sites in the United
States, Canada, Europe, and Asia. The MRI substudy
was conducted at ten sites with the capability and will-
ingness to participate. All patients enrolled at participat-
ing substudy sites were included in the MRI substudy.
GO-RAISE patients were adults with definite AS (for
≥3 months) according to modified New York criteria, a
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) score ≥4 (0- to 10-point scale), a total back
pain score ≥4 on a visual analogue scale (0- to 10-cm
scale), and an inadequate response to current or previ-
ous nonsteroidal anti-inflammatory drugs (NSAIDs). Pa-
tients were randomly assigned in a 1:1.8:1.8 ratio to
receive subcutaneous injections every 4 weeks of
placebo, golimumab 50 mg, or golimumab 100 mg.
Randomization was stratified by investigational site and
screening C-reactive protein (CRP) concentration. Patients
were allowed to continue stable doses of methotrexate,
sulfasalazine, hydroxychloroquine, corticosteroids, and
NSAIDs throughout study participation.
At week 16, patients who achieved <20% improve-
ment from baseline in both the total back pain and
morning stiffness scores entered into double-blinded
early escape, such that patients in the placebo group
received golimumab 50 mg, patients in the golimu-
mab 50 mg group received 100 mg, and patients in
the golimumab 100-mg group had no change to their
study therapy. The placebo-controlled portion of the
study ended at week 24, following which all patients
who had been receiving placebo injections crossed
over to receive golimumab 50 mg. Injections contin-
ued to be administered subcutaneously every 4 weeks
through week 252, and the last study assessments for
the period covered by the current analyses were at
week 208.
Biomarker evaluations
Serum samples collected at weeks 0, 4, and 14 of the
GO-RAISE trial were tested by Rules Based Medicine
(Austin, TX, USA) and Pacific Biomarkers (Seattle, WA,
USA) for selected markers using Luminex (Luminex,
Austin, TX, USA) and enzyme-linked immunoassay plat-
forms, respectively. The extensive list of candidate bio-
markers implicated from previous studies (Additional
file 1: Table S1) [12] was selected for correlation analyses
with imaging and clinical endpoints, including leptin,
interleukin (IL)-6, tissue inhibitor of metalloproteinase
(TIMP)-1, complement component 3 (C3), intracellular
adhesion molecule (ICAM)-1, CRP, haptoglobin, and
serum amyloid-P.
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Disease activity and progression evaluations
Clinical assessments of disease activity included the
BASDAI [13] and the ASDAS employing CRP [14] de-
termined at weeks 0, 14, and 104. MRI was employed to
assess inflammation and structural changes in the spine.
Serial spine 1.5-T MRI scans of the cervical, thoracic,
and lumbar spine regions in the sagittal plane were ac-
quired at baseline, week 14, and week 104 [5]. Two
qualified readers who were blinded to treatment infor-
mation, patient identity, and chronology of the images
independently scored each sequence using modified ver-
sions of the ankylosing spondylitis spine magnetic reson-
ance imaging score for activity (ASspiMRI-a) and the
Ankylosing spondylitis spine magnetic resonance im-
aging score for chronicity (ASspiMRI-c) [15, 16].
ASspiMRI-a scoring of each vertebral unit (VU) was pre-
viously described [5]. For the modified ASspiMRI-c
score, each VU was scored as follows: 0 (normal, no le-
sions), 1 (minor fatty degeneration), 2 (much fatty de-
generation), 3 (one or two syndesmophytes), 4 (more
than two syndesmophytes), 5 (vertebral bridging with
<25% of disc length and/or bridging of one side), or 6
(vertebral fusion with >25% of disc length and/or bridg-
ing of both sides). If a fatty lesion was present in a VU
scored 3–6, it was noted. Lateral view radiographs of the
cervical and lumbar spine regions were obtained at
weeks 0, 104, and 208 and scored by two trained readers
blinded to treatment group and chronology using the
modified Stokes Ankylosing Spondylitis Spine Score
(mSASSS) method [17], as described previously [18].
Data analysis
All analyses of MRI data collected through week 104
employed observed data; missing data were not imputed.
Of the unique serum biomarkers tested in this trial, 73
had <80% of values below the lower limit of quantitation
at baseline and are included in the analyses described
herein (Additional file 1: Table S1).
A total of 4940 analyses were performed to determine
Spearman correlation coefficients describing relation-
ships between serum biomarkers at weeks 0, 4, and 14
and subsequent efficacy endpoints, including ASDAS,
BASDAI, ASspiMRI-a, ASspiMRI-c (all determined at
weeks 0, 14, and 104), and mSASSS (determined at
weeks 0, 104, and 208). Correlations at baseline were
assessed on the basis of all patients, whereas those at
follow-up time points were assessed according to ran-
domized treatment groups (placebo versus golimumab).
For all postbaseline assessments, changes from baseline
in biomarkers were used. Only correlations found to be
statistically significant after Bonferroni multiplicity-of-
testing adjustment are reported herein.
Relationships between four biomarker levels (IL-6,
leptin, TIMP-1, and C3) and changes from baseline to
week 104 in mSASSS were also assessed using a general-
ized linear model. In this model, mSASSS scores were
adjusted for VUs with fat indicated via ASspiMRI-c
score at baseline, because the presence of fatty lesions
on MRI images is a known contributor to radiographic
(mSASSS) progression [19, 20] and because these
markers affect adipocytes.
Logistic regression analyses were also conducted to as-
sess the influence of baseline and earlier (week 14)
changes in biomarker levels on the development of new
fatty lesions on a patient level (yes or no, i.e., not de-
tected by MRI at baseline but detected at week 14 or
week 104). In such analyses, all patients were combined,
with no adjustment for treatment group or multiplicity




One hundred thirty-nine patients had serum biomarker
data, and 98 of these patients at 10 sites with MRI cap-
ability participated in the GO-RAISE MRI substudy. The
vast majority of randomized patients (299 [84.0%] of
356) had pre- and posttreatment data obtained for the
GO-RAISE radiographic substudy. Of these, up to 139
patients had sera collected for biomarker evaluations,
and up to 125 underwent spine MRI scans. As re-
ported previously, the demographic and baseline char-
acteristics for the MRI substudy patients were
generally consistent with those of the overall GO-
RAISE patient population [5].
Correlations between baseline biomarker levels and
baseline disease activity
At baseline among all patients with serum biomarker
assessments (n = 98–139), significant and moderately
strong correlations were observed between ASDAS and
levels of the following serum biomarkers of inflamma-
tion: IL-6, ICAM-1, haptoglobin, serum amyloid-P, and
C3 (rs = 0.39–0.59, all p ≤ 0.01) (Table 1). As would be
expected, ASDAS correlated with CRP (rs = 0.66, p = 0.00)
(Table 1). With respect to baseline serum markers and
baseline spinal inflammation (ASspiMRI-a score) or struc-
tural lesions (ASspiMRI-c score), no significant correla-
tions were observed.
Correlations between baseline biomarker levels and
subsequent changes in measures of disease activity,
radiographic progression, and spinal inflammation
Baseline leptin level was the only significant biomarker
correlated with ASDAS clinical improvement at week
104 of golimumab treatment (rs = 0.55, p = 0.040).
Higher baseline levels of IL-6 (rs = −0.63, p = 0.009) and
TIMP-1 (rs = −0.67, p = 0.044), but not baseline CRP,
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significantly correlated with subsequent improvement in
ASspiMRI-a score (i.e., greater reduction) from baseline
to week 14 of golimumab treatment (Table 2). All other
correlations tested between baseline biomarkers and
subsequent changes in measures of disease activity or
spinal inflammation yielded insignificant relationships.
Using a generalized linear model to assess the ability
of baseline serum leptin, C3, TIMP-1, and IL-6 levels to
predict subsequent change in mSASSS, only baseline
serum IL-6 levels were found to significantly predict
change in mSASSS at week 104 (β = 0.236, SE = 0.073,
p = 0.002, model R2 = 0.093; data not shown). Results
of logistic regression analyses indicated that baseline
levels of inflammatory and metabolic markers leptin,
C3, and TIMP-1 were statistically significant factors
in the development of new fatty lesions in the spine
at both week 14 and week 104 of golimumab treat-
ment. Change from baseline to week 14 in TIMP-1
also significantly factored into the development of
fatty lesions at week 104 (Table 3). Whereas most of
these predictive relationships were very weak, those
between higher baseline C3 levels and the seven- to
eightfold lower risk of subsequent fatty lesion devel-
opment were of note.
Results of a separate generalized linear model used to
evaluate potential interactions between biomarkers and
baseline patient characteristics show that IL-6, leptin,
TIMP-1, and C3 influenced mSASSS progression inde-
pendently of demographic factors of age, sex, and hu-
man leukocyte antigen B27 positivity (data not shown).
Correlations between posttreatment biomarker levels and
posttreatment measures of disease activity and spine
inflammation
Reductions in C3 observed from baseline to week 4
(rs = 0.55, p = 0.001) and week 14 (rs = 0.49, p = 0.040)
significantly correlated with improvement from baseline
to week 14 in the BASDAI score. Similarly, improve-
ment from baseline to week 4 in serum IL-6 (rs = 0.61,
p = 0.022) and C3 (rs = 0.72, p = 0.005) levels, as well as
improvement from baseline to week 14 in serum IL-6
levels (rs = 0.59, p = 0.043), correlated significantly with
improvement in ASspiMRI-a scores from baseline to
week 14 of golimumab treatment (Table 2). All other
correlations tested between posttreatment biomarker
levels and posttreatment measures of disease activity or
spinal inflammation yielded insignificant relationships.
Discussion
The search for serum biomarkers of prognostic utility in
AS reflects, in part, the need for objective measures of
disease activity and response to treatment, as well as the
unresolved issues of pathogenesis in the disease. The
Table 1 Correlations between baseline serum biomarker levels
and baseline ASDAS
Baseline ASDAS Spearman correlation
coefficient (rs)
Baseline serum biomarker Patients (n) rs Bonferroni-adjusted
p value
IL-6 132 0.59 0.000
ICAM-1 139 0.39 0.011
C3 98 0.53 0.000
CRP 98 0.66 0.000
Haptoglobin 98 0.46 0.010
Serum amyloid-P 98 0.50 0.001
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score employing
C-reactive protein, CRP C-reactive protein, C3 Complement component 3,
ICAM-1 Intracellular adhesion molecule-1, IL Interleukin
Table 2 Significant correlations between serum biomarkers and
Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing
Spondylitis Disease Activity Index, and ankylosing spondylitis
spine magnetic resonance imaging score for activity changes
among golimumab-treated patients
Serum biomarker, time, number
of golimumab-treated patients
Spearman correlation coefficient (rs);
Bonferroni-adjusted p-value with
respective outcome
Change in ASDAS from baseline
to week 104
Leptin
Baseline, n = 58 0.55; 0.040
Change in BASDAI from baseline
to week 14
C3
Change from baseline to week 4,
n = 76
0.55; 0.001
Change from baseline to week 14,
n = 76
0.49; 0.040
Change in ASspiMRI-a score from
baseline to week 14
IL-6
Baseline, n = 48 −0.63; 0.009
Change from baseline to week 4,
n = 48
0.61; 0.022




Baseline, n = 35 −0.67; 0.044
C3
Change from baseline to week 4,
n = 35
0.72; 0.005
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score employing
C-reactive protein, ASspiMRI-a Ankylosing spondylitis spine magnetic resonance
imaging score for activity, BASDAI Bath Ankylosing Spondylitis Disease Activity
Index, C3 Complement component 3, IL Interleukin, TIMP-1 Tissue inhibitor
of metalloproteinase-1
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structured nature of a randomized controlled trial pro-
vides more clinical uniformity in treatment regimen and
outcome measures than is possible in real-world obser-
vational studies. In the present study, significant and
moderately strong correlations were observed between
ASDAS and levels of IL-6, ICAM-1, haptoglobin, serum
amyloid-P, and C3. As expected, similar results were ob-
served for CRP. These correlations suggest possible roles
for these biomarkers in AS-related inflammation. Base-
line serum IL-6 and TIMP-1, as well as reductions in IL-
6 and C3, correlated with reduction in ASspiMRI-a
scores. Of note, ASDAS has been shown to correlate
well with ASspiMRI-a scores, and weakly with BASDAI
change, among golimumab-treated patients with AS [5].
Decreases in TIMP-1 at week 14 correlated with fatty
lesion development at weeks 14 and 104. The biological
basis of local inflammation being associated with repara-
tive processes in spine and local inflammation being
reflected as new fatty lesions have yet to be defined, and
TIMP-1 would be a candidate factor for future studies.
Previously described predictors, such as insulin, matrix
metalloproteinase-3, vascular endothelial growth factor,
or bone resorption markers, did not significantly correl-
ate with clinical or imaging outcomes.
Fatty lesion development (fat metaplasia) is thought to
reflect postinflammation “repair” and may be a precur-
sor of new bone formation. When assessed by logistic
regression, baseline levels of inflammatory and metabolic
markers leptin, C3, and TIMP-1 were statistically signifi-
cant factors in the risk of development of new fatty le-
sions in the spine at both week 14 and week 104 of
golimumab treatment, but only the relationship between
higher baseline C3 levels and a seven- to eightfold
decreased risk of subsequent fatty lesion development
offers potential clinical utility. Both leptin and C3, the
precursor of C3adesArg acylation-stimulating protein,
are involved in triglyceride uptake into adipocytes and
homeostasis of adipose tissue. Deficiency of leptin is as-
sociated with lipodystrophy and resistance to obesity,
whereas increased C3 is linked to increased central obes-
ity and insulin resistance [21]. Furthermore, inflamma-
tory cytokines such as TNF-α and IL-6 stimulate
production of leptin and C3, and decreased levels of the
receptor for C3adesArg, C5L2 [21, 22]. Together with
these properties of leptin and C3, our finding that in-
creased baseline levels of leptin and C3 were correlated
with decreased risk of vertebral fatty lesion development
suggests that these are key regulators of local adipogene-
sis within bone tissue in AS. Although Li and colleagues
also demonstrated underexpression of C3 in patients
with AS (n = 6) relative to healthy volunteers (n = 6) in a
preliminary search for disease-associated proteins in the
sera of patients with AS [23], additional studies are
needed to confirm these findings.
Limitations
A limitation of the present study is the large number of
analytes, which precludes analyses such as principal
component analysis or supervised cluster analysis. To
guard against identifying a false-positive relationship be-
tween the large number of analytes assessed and disease
activity outcomes, we employed the Bonferroni correc-
tion in the statistical modeling to account for multipli-
city of testing. The crossover to active anti-TNF agent
after a relatively short placebo period complicates inter-
pretation of “placebo group” imaging data at weeks 104
and 208. These analyses are also limited by the fact that
golimumab doses were combined and not assessed indi-
vidually; however, given that no dose-response relation-
ship was observed between golimumab 50 mg and
100 mg when analyzed by randomized groups at week
104 [4], the doses were combined to maximize the patient
numbers in the golimumab arm. Despite this approach,
there remained few patients on whom to base correlation
analyses for radiographic progression and development of
fatty lesions. This is an unresolved issue and should be the
focus of future research in this field. Additionally, IL-6
levels can be influenced by therapeutic corticosteroid use
via suppression of endogenous cortisol levels [24, 25] and
also by visceral fat secretion [26]; our analyses did not ad-
just for these potential confounders in assessing relation-
ships between IL-6 and MRI-detected spinal inflammation
and clinical measures of disease activity.
Conclusions
An extensive serum biomarker analysis in golimumab-
treated patients with AS demonstrated that few biomarkers
Table 3 Logistic regression analysis of serum biomarkers and
fatty lesion development visualized by magnetic resonance
imaging
Fatty lesion development, odds ratio
(95% confidence interval); p value






















Abbreviations: C3 Complement component 3, TIMP-1 Tissue inhibitor
of metalloproteinase-1
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showed correlation with disease activity or MRI changes in
multiparametric analysis. Although IL-6 weakly correlated
with radiographic progression, other biomarkers found in
prior studies to be significantly associated with AS imaging
changes were not confirmed.
Additional file
Additional file 1: Table S1. Serum biomarker panel. Table provides a
detailed list of the serum biomarkers evaluated. (DOCX 24 kb)
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